ReviewAmerican journal of physiology. Regulatory, integrative and comparative physiology2026
The CX3CL1-CX3CR1 axis in HIV-associated inflammation and cardiometabolic disease.
Review in American journal of physiology. Regulatory, integrative and comparative physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The chemokine fractalkine (CX3CL1)-chemokine (CX3C motif) receptor 1 (CX3CR1) axis, comprising the chemokine fractalkine (CX3CL1) and its immune cell receptor CX3CR1, links immune activation to vascular pathology in people with human immunodeficiency virus (HIV; PWH). Chronic inflammation persists in PWH despite viral suppression with antiretroviral therapy and contributes to high rates of cardiometabolic comorbidities. This is partly due to dysregulated leukocyte trafficking and endothelial activation. This review synthesizes preclinical, genetic, and clinical evidence on the multifaceted roles of CX3CR1 across immune, vascular, and cardiometabolic processes. CX3CR1 is expressed on monocyte and cytotoxic T cell subsets implicated in endothelial injury, tissue trafficking, and plaque progression. On the other hand, CX3CL1 is expressed on activated endothelial and stromal cells, which promotes leukocyte adhesion and recruitment into inflamed tissues. In PWH, persistent immune activation and cytomegalovirus coinfections are associated with the expansion of differentiated CX3CR1-expressing T cell populations, supporting the relevance of this pathway to HIV-associated inflammatory comorbidities. At the genetic level, CX3CR1 polymorphisms, including V249I and T280M, alter receptor signaling and have been associated with HIV disease progression and cardiovascular disease risk, highlighting CX3CR1 as both a biomarker and potential mediator of immune-driven pathology. Across preclinical models, pharmacological targeting of CX3CR1 or CX3CL1 attenuates inflammation, fibrosis, and vascular injury in the selected disease contexts. However, the effects of CX3CR1 signaling are tissue- and cell type-specific, and blockade may carry potential risks in settings where CX3CR1 supports immune surveillance, mucosal repair, or macrophage homeostasis. This review evaluates the therapeutic promise and safety considerations of targeting the CX3CL1-CX3CR1 axis in HIV-associated cardiovascular and inflammatory comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.